Cannabinoids, Blood-Brain Barrier, and Brain Disposition

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Cannabinoids, including delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), possess therapeutic properties such as analgesia and anti-inflammatory effects.
• Their lipophilicity and neurological activity suggest potential for treating central nervous system (CNS) diseases.
• However, THC and CBD exhibit distinct blood-brain barrier (BBB) penetration and brain disposition characteristics.

Purpose of the Study:

• To provide an overview of how THC and CBD cross the BBB and their subsequent brain disposition.
• To explore the role of CBD in mitigating BBB dysfunction caused by inflammation and ischemia.
• To discuss the potential of cannabinoids in managing drug-resistant neurological and psychiatric disorders.

Main Methods:

• Literature review of studies investigating cannabinoid transport across the BBB.
• Analysis of research on CBD's effects on BBB integrity under inflammatory and ischemic conditions.
• Examination of cannabinoid administration routes and their impact on brain delivery.

Main Results:

• CBD may counteract inflammatory cytokine damage to the BBB and ameliorate ischemia-induced dysfunction.
• Cannabinoids might enhance cognitive function by preserving BBB cerebrovascular structure and function.
• Different administration routes (subcutaneous, oral, pulmonary) influence cannabinoid brain delivery.

Conclusions:

• CBD demonstrates therapeutic potential for CNS diseases involving ischemia and inflammation due to its protective effects on the BBB.
• Cannabinoids' ability to cross the BBB is crucial for their potential in treating neurological and psychiatric conditions, including epilepsy and schizophrenia.
• Protecting BBB integrity is a key mechanism through which cannabinoids may offer neuroprotective benefits.